Entries by jackrabbit

December 12, 2014 – RNA Viruses: Biology and Countermeasures

FujiFilm and MediVector, together with Cell Host & Microbe are sponsoring a scientific Symposium on Influenza on December 12 at the American Academy of Arts & Sciences. Speakers: Ian Wilson, The Scripps Institute Broad Neutralization of Influenza Virus and Implications for Vaccine Design Sean Whelan, Harvard Medical School RNA synthesis machines of negative-strand viruses Stephen […]

DoD’s BioDefense Therapeutics Announces First Patient Enrolled in Phase 3 Clinical Trials for Favipiravir

BioDefense Therapeutics (BD Tx)—a Joint Product Management office within the U.S. Department of Defense (DoD)—announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir (T-705a). The drug is an investigational flu treatment candidate with broad-spectrum potential being developed by BD Tx through a contract with Boston-based MediVector, Inc. Read more. 

DoD’s BioDefense Therapeutics Announces Positive Results for Flu Treatment Drug

The successful completion of a Phase 2 double blind placebo-controlled clinical trial for the anti-influenza drug, T-705a (favipiravir), clears the way for Phase 3 clinical trials to begin in November. The investigational drug candidate is being developed by BioDefense Therapeutics (BD Tx)—a Joint Product Management office within the U.S. Department of Defense (DoD)—through a contract […]

MediVector Gets DoD Contract to Develop Flu Treatment

The Department of Defense’s (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded a $138.5M contract to MediVector, Inc. to further develop Favipiravir (T-705), a broad-spectrum therapeutic against multiple influenza viruses, including the 2009 H1N1 pandemic virus and drug resistant influenza strains. The contract will help bolster the protection of the Joint Forces against naturally […]

JPM-TMT Announces Contract Award for Advanced Development of Broad-spectrum Influenza Drug

The Department of Defense’s (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded a $138.5M contract to MediVector, Inc. to further develop Favipiravir (T-705), a broad–spectrum therapeutic against multiple influenza viruses, including the 2009 H1N1 pandemic virus and drug resistant influenza strains. The contract will help bolster the protection of the Joint Forces against naturally […]

MediVector, Inc. Awarded $138.5M to Advance Development of Emerging Infectious Diseases Medical Countermeasure Drug

MediVector, Inc., Boston, Mass., is being awarded a $138,500,000 cost-plus-fixed-fee contract for advance development of emerging infectious diseases medical countermeasure drug for the Federal Drug Administration licensure. Work will be performed in Boston, Mass., and is expected to be completed April 2016. Contract funds will not expire at the end of the current fiscal year. […]